213
Views
4
CrossRef citations to date
0
Altmetric
Urology

Effects of short and long-term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: A pilot study

, , , &
Pages 97-101 | Received 13 Sep 2011, Accepted 18 Nov 2011, Published online: 18 Jan 2012
 

Abstract

Objective. The aim of this study was to determine the relative calcium-reducing effects of indapamide at 6 and 18 months using a dose of 1.5 mg/day. Material and methods. Twenty-two patients with idiopathic hypercalciuria and calcium oxalate dihydrate urinary stone disease (minimum one stone episode) were selected. Each patient began a therapy regime of 1.5 mg indapamide sustained release taken once a day in the evening. Under basal conditions and after 6 and 18 months of treatment, subjects submitted urine and blood samples for analysis. The primary aim of this study was to assess the effects on excretion and concentration of calcium in urine. Results. For 2 h urine, there was a mean decrease in urinary calcium concentration of 47%, whereas urinary calcium concentrations decreased by 53% in 24 h urine (p < 0.05) at 6 months of treatment. Blood urate levels rose by 19% (p < 0.05). Treatment for 18 months resulted in significant reduction in urinary calcium levels, by approximately 48% (p < 0.05) in both 2 h and 24 h urine. A 21% increase in urate levels in the blood was observed (p < 0.05). The remaining parameters remained unaltered. Conclusions. Owing to the low effective dosage of indapamide (1.5 mg/day) and the lack of any severe side-effects, this drug would appear to be a good candidate for use in the control of hypercalciuria. As such, it could prove efficacious in the prevention of recurrent kidney stones that are often associated with this condition.

Acknowledgements

This work was supported by Fundació Barceló (Ref. 1458/2007) and project grant CTQ 2010-18271 from the Ministerio de Ciencia e Innovación del Gobierno de España.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.